Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 406 participants.

Also called NCT06579105

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 406 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06579105
  • EU CT 2024-512562-34-00
Other papers using this trial's data
  • Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial Lancet (London, England), 2026-06-20 DOI, PubMed 42259343

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada, Germany, Hungary, Japan, Poland, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06579105. Randomized; triple masking; primary purpose treatment. Start 2024-10-08 (actual); primary completion 2025-12-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Acronym
SOLSTICE
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo (placebo matching AZD5004 film-coated tablet)
Intervention (Drug)
AZD5004
Intervention (Drug)
Semaglutide
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06579105
Content hash
2a6b6800f8eba6435bce22124ff5ddecdfb9485af1ef4844682a30e4b2a6940b